Table 2. Logistic regression of predictive factors for no residual disease after secondary cytoreductive surgery (univariate analysis).
| Variables | Category | No. | OR (95% CI) | p-value* |
|---|---|---|---|---|
| Age (yr) | Continuous | 69 | 0.98 (0.92–1.04) | 0.614 |
| PCI | Continuous | 49† | 0.90 (0.81–0.99) | 0.042 |
| Disease-free interval | Continuous | 69 | 1.01 (0.96–1.06) | 0.544 |
| CA125 at recurrence | Continuous | 63 | 0.99 (0.99–1.00) | 0.440 |
| Type 1st cytoreduction | Residual disease | 10 | Reference | 0.442 |
| No residual disease | 54 | 0.50 (0.08–2.92) | ||
| High-grade serous | No | 15 | Reference | 0.348 |
| Yes | 54 | 2.80 (0.32–24) | ||
| Stage at diagnosis | I-II | 8 | Reference | 0.865 |
| III-IV | 61 | 0.82 (0.09–7.53) | ||
| ECOG | 0 | 63 | 8.0 (1.34–47.5) | 0.022 |
| 1 | 6 | Reference | ||
| Peritoneal disease (PET) | No | 28 | Reference | 0.510 |
| Yes | 41 | 1.56 (0.40–6.0) | ||
| Number of lesions PET | ≤2 | 53 | 4.36 (1.07–17.7) | 0.039 |
| >2 | 16 | Reference | ||
| AGO score | Negative | 9 | Reference | 0.528 |
| Positive | 57 | 1.75 (0.30–9.97) | ||
| iModel | Low risk | 59 | 5.57 (1.02–30.2) | 0.047 |
| High risk | 7 | Reference | ||
| MSK criteria | No | 5 | Reference | 0.012 |
| Offer/Consider | 64 | 12.2 (1.73–86.1) | ||
| PET/CT-AGO score | Negative | 22 | Reference | 0.193 |
| Positive‡ | 47 | 0.40 (0.10–1.58) | ||
| PET/CT-iMODEL | Negative | 20 | Reference | 0.028 |
| Positive‡ | 49 | 4.82 (1.18–19.5) | ||
| PET/CT-MSK criteria | Negative | 18 | Reference | 0.014 |
| Positive‡ | 51 | 5.87 (1.42–24.1) |
AGO, Arbeitsgemeinschaft Gynäkologische Onkologie; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; MSK, Memorial Sloan Kettering; OR, odds ratio; PCI, peritoneal carcinomatosis index; PET/CT, positron emission tomography/computed tomography.
*Logistic regression; †only cases with recorded PCI>0; ‡Considered positive if at least one of the two models suggested secondary cytoreductive surgery.